Altasciences and Evidence Matters Advance AI-Driven Drug Development With Nonclinical Automation Breakthrough

Contributed by: Business Wire

Logo

Tags

Research

Technology

Clinical Trials

Software

Biotechnology

Pharmaceutical

Health

Data Management

Science

Artificial Intelligence

Altasciences

More Like This

Altasciences and Evidence Matters Announce Strategic Collaboration to Advance AI-Enhanced Text Engineering for Regulatory Writing in Life Sciences

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development

CRO Leadership Awards 2024: Capabilities (Graphic: Business Wire)

Altasciences Receives 2024 CRO Leadership Award for Capabilities

From left to right: Altasciences' Dr. Lynne Le Sauteur, Dr. Susan Ohorodnik, Ian Vanterpool, and Michael Qualls at the bioanalytical laboratory opening in Columbia, Missouri (Photo: Business Wire)

Altasciences Completes Expansion of New State-Of-The-Art Laboratory in Columbia, Missouri

Florence Announces AI-Assisted Workflows to Transform Clinical Trials

Altasciences’ Commitment to Supporting Pharma and Biotech With Comprehensive Bioanalytical Services

PR Newswire associated0

Elsevier launches PharmaPendium AI, designed to support faster and more reliable access to regulatory insights for drug development

PR Newswire associated0

Survey: Unsustainable Regulatory Workloads Leave No Choice About AI Adoption